ASA EFFECTS ON ANTIHYPERTENSIVE EFFICACIES OF ENALAPRIL AND LOSARTAN

本研究旨在研究81 mg和325 mg阿司匹林(ASA)对依那普利和氯沙坦个体降压能力的影响。第二个目标是通过测量尿前列腺素浓度来描述观察到的ASA与氯沙坦或ASA与依那普利之间的相互作用。无效假设是，在依那普利或氯沙坦的单一治疗方案中加入低剂量或平均剂量的ASA时，血压没有差异。共招募18名受试者，每组9名，分别服用依那普利或氯沙坦。这项研究包括3，2周的治疗周期，分别使用ASA 81 mg，ASA 324 mg或安慰剂，每个疗程间隔2周冲洗期。将通过袖带测压收集坐位血压，并收集12小时尿并分析PGE2、PGE-M、6-keto-PGF1α、2，3-dior-PGI-M、TXB2和Tx-M。血浆去甲肾上腺素浓度也将被收集。只有在安慰剂和ASA治疗期间观察到的血压有统计学差异时，才会进行尿液和血浆的分析和比较。

This research is designed to study the effects of 81 mg and 325 mg of aspirin (ASA) on the individual abilities of enalapril and losartan to lower blood pressure. A secondary objective is to characterize any observed interaction between ASA and losartan or ASA and enalapril by measuring urinary prostanoid concentrations. The null hypothesis is that there is no difference in blood pressure when a low dose or average dose of ASA is added to a monotherapy regimen of either enalapril or losartan. A total of 18 subjects will be recruited, 9 each taking enalapril or losartan. The study involves a 3,2 week treatment periods with either ASA 81 mg, ASA 324 mg or placebo each separated by 2 week washout periods. Sitting BP will be collected via cuff manometry and 12-hour urine collections will be completed and analyzed for PGE2, PGE-M, 6-keto-PGF1alpha, 2,3 dinor-PGI-M, TXB2 and TX-M. Plasma norepinephrine concentrations will also be collected. Urine and plasma analyses and comparisons will only be performed if there is a statistical difference observed in blood pressure between the placebo and ASA-treatment periods.